Cardinal Health stock: CVS distribution agreement extended through June 30, 2032
Cardinal Health has extended its pharmaceutical distribution agreements with CVS Health through June 30, 2032, a renewal that continues its current scope of distribution services. The company reaffirmed its fiscal 2027 non-GAAP diluted earnings-per-share guidance of 13% to 15% growth, or $12.40 to $12.60, and its long-term guidance of 12% to 14%. Cardinal Health also announced it would release its first-quarter fiscal 2027 results on November 5, 2026.
Nearly half of U.S. adults who need mental healthcare don't know how to find it. Here's where to start
Many U.S. adults struggle to find mental healthcare due to cost, lack of information, or scarcity of providers, especially in rural areas. Online care has emerged as a significant aid in improving access and treatment outcomes, regardless of location. The article offers practical steps for finding mental health services, including utilizing insurance, seeking support from doctors or employers, exploring options for uninsured individuals, using care matching tools, understanding different provider types, and treating the first appointment as a conversational assessment.
Cardinal Health stock extends CVS deal through 2032
Cardinal Health (CAH) has extended its pharmaceutical distribution agreement with CVS Health through June 30, 2032, providing significant revenue visibility. The company reaffirmed its fiscal 2027 non-GAAP EPS guidance of USD 12.40 to USD 12.60, representing 13-15% growth. Analysts maintain a "Moderate Buy" consensus with an average target price of USD 266.56, indicating potential upside.
Wall Street Zen downgrades CVS Health stock to Buy
Wall Street Zen has downgraded CVS Health stock from "Strong Buy" to "Buy," though analyst ratings remain largely positive. Despite the downgrade, CVS Health reported strong second-quarter results with revenue up 7.30% and EPS exceeding estimates. The company has also set its fiscal 2026 earnings-per-share guidance and is scheduled to discuss third-quarter results on November 4, 2026.
CVS Health stock sets November 4 earnings date
CVS Health has scheduled November 4, 2026, for its third-quarter results following a strong second quarter where it reported adjusted EPS of USD 2.58, above consensus. Analysts maintain a "Moderate Buy" rating with an average price target of USD 107.24. Additionally, an ex-dividend date of October 22, 2026, and a dividend payment date of November 2, 2026, for a USD 0.665 quarterly dividend have been set.
CVS Health Corporation (NYSE:CVS) Stock Has Average Target Price of $107.24
Analysts maintain a "Moderate Buy" rating for CVS Health Corporation (NYSE:CVS), with an average 12-month price target of $107.24, significantly higher than its current share price of $86.94. The company's recent quarterly earnings surpassed expectations, reporting $2.58 EPS and $106.10 billion in revenue, an increase of 7.3% year-over-year. Institutional investors hold a substantial 80.66% stake in CVS, with major firms like BlackRock and State Street increasing their positions.
McKesson stock gains 2.06 percent as CVS pact extends to 2032
McKesson stock rose 2.06% on October 5, 2026, driven by the planned extension of its pharmaceutical distribution agreement with CVS Health through June 2032. The company reaffirmed its fiscal 2027 adjusted EPS guidance and long-term growth target. Despite the stock trading below its yearly high, analysts maintain a "Moderate Buy" consensus, with an average target price 5.71% above the current trading price.
Danaher Corp Stock (DHR) Moved Up by 3.32% on Oct 5: What Investors Need To Know
Danaher Corp (DHR) saw its stock rise by 3.32% on October 5, driven by favorable analyst revisions, a rebound in biopharmaceutical funding, and positive market sentiment following a structured CEO transition. The company, which reported annual revenue of $24.57B and net profit of $3.61B, outperformed its sector peers. Technical indicators suggest a neutral to buy condition, though risks like leadership transition friction and bioprocessing equipment order deferrals remain.
Illumina Inc Stock (ILMN) Moved Up by 7.85% on Oct 5: Drivers Behind the Movement
Illumina Inc. (ILMN) stock rose by 7.85% on October 5th, driven by significant price target increases from Wall Street firms like RBC Capital due to accelerating clinical sequencing demand and AI applications in life sciences. The company's NovaSeq X platform's strong placement velocity and improved operating margins also contributed to the positive sentiment. Technical indicators showed a MACD buy signal, though the stock was in an overbought condition according to Williams %R.
Cardinal Health stock gains 1.59 percent after CVS pact
Cardinal Health's stock rose by 1.59% after confirming an extended pharmaceutical distribution agreement with CVS Health until June 30, 2032. This deal secures a major customer relationship and reinforces the company's fiscal 2027 non-GAAP EPS guidance of $12.40-$12.60. Analysts maintain a "Moderate Buy" consensus with a target price significantly above the current trading value, and investors await the Q1 fiscal 2027 results in November.
Fall into wellness: Preventive health tips for older adults, a Q&A with Jean Reidy
This article provides preventive health tips for older adults as fall approaches, featuring a Q&A with Jean Reidy, an Adult Nurse Practitioner at Oak Street Health. She emphasizes the importance of annual wellness visits, recommended vaccinations, and preventive screenings. Reidy also highlights the significance of mental health awareness, especially during colder months, and encourages proactive healthcare steps.
Is Coca-Cola (NYSE:KO) Still a Dividend King Worth Watching?
Coca-Cola (NYSE:KO) continues to be a notable dividend king, having recently delivered another quarterly cash dividend and confirming its third-quarter results date. The company's consistent dividend increases over decades highlight its strong cash generation and disciplined capital management. Despite evolving consumer tastes and industry challenges, Coca-Cola's robust brand portfolio and extensive distribution network keep it a key player in the defensive consumer staples sector.
Why Is Bank of America (NYSE:BAC) in Focus as Earnings Season Nears?
Bank of America (NYSE:BAC) is drawing attention as earnings season approaches, driven by its expansion of a generative AI platform in global payments and market focus on deposit trends and the rate environment. As one of the largest deposit-gathering institutions, its financial performance and commentary offer insights into the broader economy and consumer health. The bank's substantial trading desks, wealth management, and continuous technology investments also contribute to its prominent position in the financial sector.
CVS will discuss quarterly results Nov. 4. Its webcast will stay online for a year.
CVS Health (NYSE: CVS) has announced it will hold its third-quarter 2026 earnings conference call on November 4, 2026, at 8:00 a.m. ET. The event will include a discussion of financial results with analysts and investors, and an audio webcast will be available and archived on the company's investor relations website for one year.
McKesson extends CVS Health pact through 2032: CVS Health stock yields 3.10 percent
McKesson has extended its pharmaceutical distribution partnership with CVS Health through June 2032, covering various pharmacy channels. The agreement, though commercial terms were not disclosed, signifies a long-term distribution relationship for CVS Health. The company reported strong second-quarter revenue of $106.10 billion and raised its full-year 2026 adjusted earnings guidance, while its stock currently yields 3.10 percent.
McKesson stock extends CVS pact through 2032 with guidance intact
McKesson has extended its agreement to supply CVS Health pharmacies and distribution centers through June 2032, reaffirming its fiscal 2027 adjusted EPS guidance of USD 44.20-45.00 and a long-term EPS growth target of 13%-16%. The company's recent quarterly revenue reached USD 105.38 billion, exceeding analyst expectations. McKesson stock closed at USD 902.28 on October 2, 2026, and its next earnings update is scheduled for November 4, 2026.
CVS Health stock gains 1.48 percent as analysts stay positive
CVS Health stock saw a 1.48% gain, closing at $86.46 on October 2, 2026, with analysts maintaining a positive outlook and a consensus target of $107.24. The company reported strong second-quarter 2026 revenues of $106.1 billion, up 7.3% year-over-year, and raised its full-year adjusted EPS guidance. Cantor Fitzgerald reiterated an "Overweight" rating with a $110.00 price target.
McKesson stock trades at USD 902.28 after CVS deal
McKesson stock is trading at USD 902.28 following a new distribution agreement with CVS that extends through June 2032. The company reaffirmed its fiscal 2027 adjusted EPS guidance of USD 44.20-45.00, despite the agreement being in principle. McKesson reported strong fiscal 2027 first-quarter revenue of USD 105.38 billion, beating estimates, and is preparing for its Q2 earnings call on November 4, 2026.
CVS Health stock rises 1.48 percent as Evercore sets USD 125.00 target
CVS Health stock increased by 1.48% after Evercore ISI maintained a Buy rating and set a USD 125.00 price target. The company reported strong Q2 2026 results, with adjusted EPS up 42.5% and management raising full-year 2026 guidance for EPS, revenue, and operating cash flow. Despite the positive outlook and analyst target, the stock remains significantly below its 52-week high.
ALPS Group calls for Filipinos to take a more proactive approach to health
ALPS Group Inc., a Malaysia-based biotechnology and wellness company, is advocating for Filipinos to adopt a proactive approach to healthcare, focusing on prevention, early detection, and personalized health management. This initiative comes as noncommunicable diseases were responsible for 68% of deaths in the Philippines in 2021. ALPS Group aims to expand its presence in the Philippines and integrate its ecosystem of health assessments, precision medicine, and wellness recommendations into daily life.
At $21.59 each, RGC Resources (RGCO) VP buys 9 shares through a stock purchase plan.
Lawrence T. Oliver, Senior VP and Secretary of RGC Resources Inc. (RGCO), purchased 9 shares of common stock at $21.59 per share on October 1, 2026. This transaction was made through an optional cash contribution via the company's Dividend Reinvestment and Stock Purchase Plan. Following the purchase, Oliver directly holds 30,165 shares.
UnitedHealth Reports on Oct. 13. Here's the 1 Number I'm Watching.
UnitedHealth Group is scheduled to report its third-quarter financial results on October 13. While investors will scrutinize revenue and earnings per share, the author emphasizes the importance of the medical care ratio, which indicates the percentage of premiums paid out for claims. This metric is crucial for assessing the insurer's profitability and will reveal if UnitedHealth maintained its efforts to lower it.
In-network colonoscopies and mammograms will have $0 copays under Aetna's 2027 Medicare plans.
Aetna, a CVS Health company, announced its 2027 Medicare Advantage plans will expand to 41 states and Washington, D.C., reaching 57 million eligible beneficiaries. Key features include $0 copays for Tier 1 prescription drugs, annual physicals, colonoscopies, and mammograms for in-network providers, and at least one $0 monthly-premium plan in every covered county. The company also plans to expand Chronic Condition Special Needs Plans to 25 states and enhance its High Value Provider Incentive Program.
Aetna unveils 2027 Medicare plans with $0 copays, expanded benefits, and enhanced care for chronic conditions.
Aetna, a part of CVS Health, has announced its 2027 Medicare plans, featuring $0 copays for Tier 1 drugs, vaccines, and preventive services. The plans will expand to 25 states for chronic conditions and enhance benefits like dental, vision, and fitness memberships, alongside improved digital tools. This initiative aims to provide affordable and quality care to 57 million Medicare-eligible beneficiaries, reinforcing CVS Health's strong position in the healthcare sector.
Cardinal Health extends CVS deal. What it means for Cardinal Health stock
Cardinal Health has extended its pharmaceutical distribution agreement with CVS Health through June 30, 2032. The company also reaffirmed its fiscal year 2027 non-GAAP earnings per share guidance, projecting 13% to 15% growth. The Cardinal Health stock traded flat at EUR 202.90 in weekend trading after the announcement.
How CVS Deal Extension At Cardinal Health (CAH) Has Changed Its Investment Story
Cardinal Health extended its pharmaceutical distribution agreement with CVS Health until June 30, 2032, maintaining its current service scope and reaffirming its fiscal 2027 non-GAAP EPS growth guidance. This extension solidifies a key partnership, supporting Cardinal Health's long-term planning for specialty distribution expansion and mix shift towards higher-margin services. The upcoming fiscal 2027 Q1 results on November 5 will provide further insight into how this agreement fits into the company's guidance and capital allocation priorities.
Lost Money on ARS Pharmaceuticals, Inc. (SPRY)? Urged to Join Class Action Before October 5, 2026 - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has filed a securities class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) on behalf of investors who suffered losses due to alleged securities fraud between March 9, 2026, and June 24, 2026. The lawsuit claims that the company made misleading statements regarding expanded insurance coverage for its product, neffy, through CVS Caremark. Investors are urged to join the class action before October 5, 2026, to explore potential recovery.
CVS Health (NYSE:CVS) Stock Moved Down to "Buy" by Wall Street Zen
Wall Street Zen downgraded CVS Health (NYSE:CVS) from "strong buy" to "buy," though the overall analyst consensus remains a "Moderate Buy" with an average price target of $107.24. CVS recently reported strong quarterly results, beating EPS estimates with $2.58 and achieving revenues of $106.10 billion, up 7.3% year-over-year. Institutional investors continue to hold a substantial 80.66% stake in the company, with major firms like BlackRock and State Street increasing their positions.
What Dementia Care Really Costs and How to Prepare
Dementia care is a significant financial burden due to its long duration and increasing care needs as the disease progresses. Costs can range from hundreds of thousands to over a million dollars, with national median monthly expenses for different care types presented. Families typically cover these costs through out-of-pocket payments, long-term care insurance, or Medicaid as a last resort, emphasizing the importance of early financial planning.
MinuteClinic is helping connect more Americans to care
MinuteClinic is expanding access to care by offering affordable and convenient in-person, virtual, and digital health options, addressing issues like long wait times and high costs. It provides services ranging from acute illness treatment and preventive care to chronic condition management and weight loss support. The initiative also aims to help close the primary care gap by offering accessible ongoing care through its clinics and virtual platforms.
Q2 Earnings Highlights: Alignment Healthcare (NASDAQ:ALHC) Vs The Rest Of The Health Insurance Providers Stocks
This article analyzes the Q2 earnings performance of Alignment Healthcare (NASDAQ:ALHC) and compares it to other health insurance providers. While the overall sector showed strong Q2 results, many companies, including ALHC and CVS Health, experienced stock price declines despite beating revenue estimates. The article also touches on market risks like AI's long-term impact and geopolitical events, while highlighting top and weakest performers in the health insurance sector.
UnitedHealth and Humana cutting Medicare Advantage plans in 2027
UnitedHealth and Humana are discontinuing Medicare Advantage plans covering over one million seniors, with CVS Health's Aetna and Centene also scaling back. This move is a response to rising medical costs and insufficient government reimbursement, leading to insurers pulling back from less profitable markets for the 2027 enrollment year. Affected members will need to select new plans, and UnitedHealth will restructure its offerings to focus on lower-cost options.
Settling into college: Five ways students can take charge of their health
This article provides five practical steps for college students to take charge of their health and build independence. It covers medication management, identifying healthcare resources, establishing healthy routines, keeping essential health supplies on hand, and planning for health and wellness expenses. The aim is to equip students with skills for managing their health beyond their college years.
CVS Health declares dividend as Cantor targets CVS Health stock at USD 110.00
CVS Health has declared a quarterly dividend of USD 0.665 per share, following a strong second quarter where revenue increased by 7.30% to USD 106.10 billion and adjusted earnings per share rose by 42.50%. Cantor Fitzgerald reiterated an Overweight rating and a USD 110.00 price target for CVS Health stock. The company also raised its fiscal 2026 adjusted earnings guidance, indicating a broader recovery despite ongoing operational variables in its diverse business segments.
Cardinal Health, McKesson Extend CVS Distribution Deals to 2032
Cardinal Health and McKesson have extended their pharmaceutical distribution agreements with CVS Health through June 2032, securing their largest customer for an additional six years. Cardinal Health's deal is a binding letter of intent, while McKesson's is an agreement in principle, with definitive contracts still pending. These extensions are significant as CVS Health represents a substantial portion of both distributors' revenues, accounting for 28% of Cardinal Health's FY2026 revenue and approximately 24% of McKesson's consolidated revenues for the same period.
Cardinal Health agrees to extend CVS deal: Cardinal Health stock gains 1.33 percent
Cardinal Health has extended its pharmaceutical distribution agreement with CVS Health until June 30, 2032, providing long-term volume security. The company reaffirmed its fiscal year 2027 non-GAAP earnings per share growth guidance of 13% to 15%. This announcement led to a 1.33% gain in Cardinal Health's stock price, with shares trading at EUR 206.35.
CVS Health: After 30 Years, a Hepatitis C Treatment That Finally Worked
Mary, who lived with hepatitis C for over 30 years, was successfully cured thanks to personalized care from Oak Street Health and CVS Specialty Pharmacy. An initial obstacle with medication size was overcome by finding an alternative formulation, showcasing the value of integrated health care and coordinated support in chronic disease management. This collaborative effort led to a life-changing outcome for Mary, highlighting the importance of a committed care team.
Grail’s cancer blood test nears landmark FDA approval, but insurance coverage looms
Grail's Galleri blood test is close to FDA approval, which would be a significant step towards wider adoption. However, securing health insurance coverage from both private insurers and government programs like Medicare is the next major hurdle for the multi-cancer early detection test. Widespread coverage could lead to a multi-billion dollar market, but concerns remain regarding follow-up costs, uncertain benefits, and the need for further research to confirm its impact on reducing cancer deaths.
Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms
Grail's Galleri blood test for early cancer detection has received a positive recommendation from an FDA advisory panel, moving it closer to full approval. While FDA approval is a significant step, the critical hurdle remaining is securing widespread insurance coverage from private insurers and government health programs like Medicare. Analysts project a potential U.S. market of $60 billion annually by 2030 if the tests gain coverage, but doctors still raise concerns about follow-up costs and whether these tests definitively improve patient outcomes.
CVS renews as Cardinal Health’s largest customer through 2032
Cardinal Health Inc. has secured an early renewal of its contract with its largest customer, CVS, extending their distribution deal through 2032. CVS accounts for over a quarter of Cardinal Health's sales and has added five years to the previous agreement. This renewal highlights the continued strong business relationship between the two healthcare giants.
How Much Downside Is Left In CVS Health Stock?
CVS Health stock has fallen 12.7% in the past month, trading 22.5% below its 52-week high, despite no company-specific news. The article analyzes CVS's current financial state, noting its thin operating margins and heavy debt, which amplifies market risk. It also reviews CVS's historical performance during market shocks, particularly credit crises, where it experienced significant declines but eventually recovered.
Cigna (CI) Stock Looks Cheap Following Its 44% Five Year Gain
Cigna (CI) has seen a 43.7% gain over the past five years, but its stock is down in the last year, leading to questions about its current valuation relative to earnings. Despite a new US$3 billion modernization program and reaffirmed 2026 guidance, Cigna's P/E ratio of 11.0x is significantly lower than the broader Healthcare sector (24.3x) and its peer group (29.8x), suggesting it may be undervalued. Investors are encouraged to consider Cigna's future growth potential and analyst expectations to determine if its earnings justify its current price.
Why McKesson Stock Soared More Than 5% Higher Today
McKesson stock gained over 5% after announcing an extension of its long-standing partnership with CVS Health until June 2032. The agreement ensures McKesson will continue distributing medicines to CVS's various pharmacy operations. McKesson also reaffirmed its fiscal year 2027 and long-term earnings guidance, highlighting its strong position in the healthcare distribution market.
CVS - Managed Care Margin Recovery And Healthcare Benefits Will Shape Industry Prospects
CVS Health's fair value has slightly increased to $116.28, driven by expected managed care margin recovery, pharmacy growth, and GLP-1 related services. Analysts anticipate revenue growth of 3.6% annually over the next three years, with profit margins improving to 2.5%, leading to an undervalued stock price of $85.69. The company's focus on Aetna underwriting discipline, technology-driven cost savings, and balance sheet improvements are key factors supporting earnings stability and future growth.
One profession with endless impact: Celebrating pharmacists
This article celebrates the impactful role of pharmacists, highlighting that their work extends far beyond dispensing medication. Pharmacists are crucial in preventing hospitalizations, educating patients, and advocating for patient safety, leveraging science, problem-solving, and compassion to make a meaningful difference in individuals' health journeys. The piece emphasizes their accessibility and evolving role within healthcare, particularly across CVS Health.
Cardinal Health, McKesson Extend Distribution Pacts With CVS Through 2032
Cardinal Health and McKesson have both extended their pharmaceutical distribution agreements with CVS Health through mid-2032. Both companies reaffirmed their fiscal 2027 adjusted EPS guidance and long-term growth targets, with McKesson's shares rising 4.4% on the news. These agreements secure significant revenue streams for the distributors and provide stability in the drug distribution landscape.
Benitec Biopharma Ltd ADR (BNTC-Q) Stock Price and News - The Globe and Mail
This article provides stock price and news information for Benitec Biopharma Ltd ADR (BNTC-Q), listed on NASDAQ. It includes recent analyst ratings, company announcements regarding financial results, clinical study updates for their therapeutic BB-301, and board changes. The company specializes in DNA-directed RNA interference technology for chronic and life-threatening conditions.
Is Cardinal Health (CAH) Cheap As Its CVS Deal Extension Locks In Revenue Visibility?
Cardinal Health recently extended its distribution agreement with CVS Health through June 2032, securing long-term revenue visibility. Despite this, its share price has seen a recent pullback, leading some analysts to consider it 18% undervalued with a fair value estimate near $270.94. The company's valuation is seen as mixed, with a P/E ratio higher than the industry average but potentially justified by a shift towards higher-margin services.
Why McKesson (MCK) Stock Is Trading Up Today
Shares of McKesson (MCK) rose 4.4% after the company reached an agreement to extend its pharmaceutical distribution partnership with CVS Health through June 2032. McKesson also reaffirmed its fiscal year 2027 adjusted earnings per share forecast and its long-term adjusted earnings per share growth rate target. The stock has shown moderate volatility, and this positive news is seen as significant by the market, despite a previous dip due to a CEO stock sale.
McKesson Extends CVS Pharmaceutical Distribution Agreement Through 2032
McKesson Corp. has extended its pharmaceutical distribution agreement with CVS Health through June 2032, securing a partnership that has spanned over 25 years. This extension provides McKesson with greater visibility into a significant customer relationship as it reshapes its portfolio around pharmaceutical distribution and specialty care. Cardinal Health also announced a similar extension with CVS Health, highlighting CVS's strategy to ensure continuity in its pharmaceutical supply chain with major distributors.
